Specialized Hospital For Active Treatment Of Pneumo-Physiatiric Diseases Dr. Treiman EOOD
- Address
- lock Available on a paid plan
Specialized Hospital For Active Treatment Of Pneumo-Physiatiric Diseases Dr. Treiman EOOD
The Specialized Hospital for Active Treatment of Pneumo-Physiatiric Diseases Dr. Treiman EOOD is a dedicated respiratory medicine center with extensive expertise in conducting advanced clinical trials for chronic respiratory conditions. The facility specializes in investigating novel therapeutic interventions and biologics for patients with moderate to severe pulmonary diseases, with a particular focus on reducing disease exacerbations and improving long-term patient outcomes.
- Chronic Obstructive Pulmonary Disease (COPD) treatment trials, including evaluation of biologics such as itepekimab and tozorakimab for reducing acute exacerbations
- Long-term safety and tolerability studies of investigational respiratory therapeutics in moderate to severe COPD populations
- Respiratory virus prevention research, including vaccine efficacy trials for Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) in older adults
The center demonstrates significant capabilities in managing complex COPD exacerbation studies involving former smokers and patients requiring add-on therapies to standard of care. Their research portfolio encompasses both monoclonal antibody therapies targeting inflammatory pathways and preventive vaccine strategies for respiratory viral infections, particularly in vulnerable populations aged 60 years and older. This comprehensive approach positions the hospital as a key contributor to advancing respiratory disease management and prevention.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Specialized Hospital For Active Treatment Of Pneumo-Physiatiric Diseases Dr. Treiman EOOD
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double‑Blind, Placebo‑Controlled Phase 2/3 Study of Subcutaneous PF‑07275315 in Adults with Moderate‑to‑Severe Chronic Obstructive Pulmonary Disease | Pfizer Inc. | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Itepekimab | 2 | Unknown | 2021-03-22 | 2024-05-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.